<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DESCRIPTION: The American College of Physicians (<z:chebi fb="65" ids="13534">ACP</z:chebi>) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> medications </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials </plain></SENT>
<SENT sid="2" pm="."><plain>Searches were limited to English-language publications </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical outcomes evaluated for this guideline included <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality, cerebrovascular morbidity, <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system </plain></SENT>
<SENT sid="5" pm="."><plain>RECOMMENDATION 1: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> when lifestyle modifications, including diet, exercise, and <z:hpo ids='HP_0001824'>weight loss</z:hpo>, have failed to adequately improve <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (Grade: strong recommendation; high-quality evidence) </plain></SENT>
<SENT sid="6" pm="."><plain>RECOMMENDATION 2: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians prescribe monotherapy with <z:chebi fb="0" ids="6801">metformin</z:chebi> for initial pharmacologic therapy to treat most patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (Grade: strong recommendation; high-quality evidence) </plain></SENT>
<SENT sid="7" pm="."><plain>RECOMMENDATION 3: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians add a second agent to <z:chebi fb="0" ids="6801">metformin</z:chebi> to treat patients with persistent <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> when lifestyle modifications and monotherapy with <z:chebi fb="0" ids="6801">metformin</z:chebi> fail to control <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (Grade: strong recommendation; high-quality evidence) </plain></SENT>
</text></document>